Quince Therapeutics Inc (QNCX)
0.91
-0.01
(-1.08%)
USD |
NASDAQ |
May 17, 16:00
0.91
0.00 (0.00%)
After-Hours: 20:00
Quince Therapeutics Enterprise Value: -15.20M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | -15.20M |
| May 16, 2024 | -14.55M |
| May 15, 2024 | -15.07M |
| May 14, 2024 | -14.98M |
| May 13, 2024 | -14.56M |
| May 10, 2024 | -13.25M |
| May 09, 2024 | -14.55M |
| May 08, 2024 | -14.98M |
| May 07, 2024 | -14.55M |
| May 06, 2024 | -12.82M |
| May 03, 2024 | -11.73M |
| May 02, 2024 | -12.82M |
| May 01, 2024 | -11.38M |
| April 30, 2024 | -8.065M |
| April 29, 2024 | -8.713M |
| April 26, 2024 | -8.497M |
| April 25, 2024 | -9.793M |
| April 24, 2024 | -8.497M |
| April 23, 2024 | -6.336M |
| April 22, 2024 | -8.497M |
| April 19, 2024 | -8.929M |
| April 18, 2024 | -8.497M |
| April 17, 2024 | -11.09M |
| April 16, 2024 | -11.24M |
| April 15, 2024 | -10.87M |
| Date | Value |
|---|---|
| April 12, 2024 | -13.56M |
| April 11, 2024 | -11.09M |
| April 10, 2024 | -11.52M |
| April 09, 2024 | -8.065M |
| April 08, 2024 | -9.361M |
| April 05, 2024 | -10.01M |
| April 04, 2024 | -9.361M |
| April 03, 2024 | -8.929M |
| April 02, 2024 | -8.929M |
| April 01, 2024 | -7.200M |
| March 28, 2024 | -15.82M |
| March 27, 2024 | -12.80M |
| March 26, 2024 | -12.80M |
| March 25, 2024 | -9.772M |
| March 22, 2024 | -10.06M |
| March 21, 2024 | -11.35M |
| March 20, 2024 | -12.21M |
| March 19, 2024 | -9.632M |
| March 18, 2024 | -10.49M |
| March 15, 2024 | -11.78M |
| March 14, 2024 | -11.78M |
| March 13, 2024 | -10.92M |
| March 12, 2024 | -10.06M |
| March 11, 2024 | -11.35M |
| March 08, 2024 | -11.57M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-73.87M
Minimum
Dec 28 2022
3.439B
Maximum
Aug 10 2021
577.20M
Average
306.26M
Median
Dec 02 2021
Enterprise Value Benchmarks
| NovaBay Pharmaceuticals Inc | 5.156M |
| Palatin Technologies Inc | 22.26M |
| iBio Inc | 16.77M |
| Theriva Biologics Inc | -8.901M |
| Oragenics Inc | 8.862M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -11.15M |
| Total Expenses (Quarterly) | 8.673M |
| EPS Diluted (Quarterly) | -0.26 |
| Earnings Yield | -83.98% |